These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Intratympanic gentamicin in Menière's disease].
    Author: Huang W, Xu H, Gao B.
    Journal: Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2004 Jan; 18(1):14-6. PubMed ID: 15088342.
    Abstract:
    OBJECTIVE: To investigate the effect and toxicity of intratympanic gentamicin injection therapy for intractable vertigo of Menière's disease. METHOD: Thirteen patients diagnosed of unilateral Menière's disease were given gentamicin 0.5 ml (26.7 mg/ml) intratympanically once a week for two weeks. All the patients were followed-up for at least two years. The result was monitored using the criteria set by Chinese Otorhinolaryngological Academy and Editorial Board of Chinese Journal of Otorhinlolaryngology in 1996. RESULT: Complete or substantial vertigo control was achieved in 12 patients (92.3%). Two weeks after treatment, the pure tone (0.5 kHz, 1.0 kHz, 2.0 kHz, 3.0 kHz) average hearing threshold had no significant change. 8.0 kHz hearing threshold increased significantly in 3 patients(23.1%). 18-24 months after treatment, the hearing threshold increased significantly in 9 patients respectively. No patient felt improved in tinnitus. CONCLUSION: Intratympanic gentamicin injection is a simple and cost-effective means for controlling intractable vertigo spelling of Menière's disease, but it also has some toxic effect to hearing.
    [Abstract] [Full Text] [Related] [New Search]